Reprogenix Bioscience Inc. is a high-tech life and health enterprise dedicated to revolutionizing the future of medicine with its advanced stem cell and regenerative medicine technology. Led by Dr. Lieming Ding, national high-level talent program expert, and Professor Hongkui Deng, Director of the Peking University Stem Cell Research Center, the company comprises a diverse team of outstanding talents from top universities around the world and has established an innovative cell therapy development platform that integrates research, production, education, and clinical translation. Powered by industry-leading proprietary stem cell technology, Reprogenix Bioscience Inc. is committed to cutting-edge innovation. The company aims to build a world-class stem cell therapy clinical translation industry platform to drive technological innovation in regenerative medicine on a national level.